Bellerophon Therapeutics, Inc. Stock Börse Stuttgart
Equities
6L7A
US0787713009
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.421 EUR | +20.98% | +26.05% | -45.08% |
04-25 | North American Morning Briefing : More Tech -2- | DJ |
04-11 | North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge | DJ |
Sales 2021 | - | Sales 2022 | - | Capitalization | 8.59M 8.03M 11.74M |
---|---|---|---|---|---|
Net income 2021 | -17M -15.9M -23.24M | Net income 2022 | -19M -17.77M -25.97M | EV / Sales 2021 | - |
Net cash position 2021 | 23.78M 22.24M 32.51M | Net cash position 2022 | 6.72M 6.29M 9.19M | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.66
x | P/E ratio 2022 |
-0.43
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 84.97% |
Latest transcript on Bellerophon Therapeutics, Inc.
1 week | +26.05% | ||
1 month | +7.12% | ||
3 months | -34.22% | ||
6 months | -95.67% | ||
Current year | -45.08% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Jalbert
CEO | Chief Executive Officer | 63 | - |
Martin Dekker
CTO | Chief Tech/Sci/R&D Officer | 51 | 15-01-28 |
Edwin L. Parsley
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Naseem Amin
CHM | Chairman | 62 | 15-06-28 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- BLPH Stock
- 6L7A Stock